Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) Director Jerry C. Griffin sold 554 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $197.81, for a total transaction of $109,586.74. Following the transaction, the director now directly owns 10,636 shares in the company, valued at $2,103,907.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Inspire Medical Systems Stock Up 2.4 %
Shares of INSP stock opened at $213.36 on Thursday. The firm’s 50-day simple moving average is $198.23 and its two-hundred day simple moving average is $181.19. Inspire Medical Systems, Inc. has a 52 week low of $123.27 and a 52 week high of $330.00.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.53. The company had revenue of $192.51 million during the quarter, compared to the consensus estimate of $186.75 million. Inspire Medical Systems had a negative return on equity of 3.93% and a negative net margin of 3.39%. The firm’s quarterly revenue was up 39.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. Research analysts expect that Inspire Medical Systems, Inc. will post -0.35 earnings per share for the current year.
Institutional Trading of Inspire Medical Systems
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the stock. KeyCorp assumed coverage on shares of Inspire Medical Systems in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $278.00 target price for the company. Mizuho restated a “buy” rating and set a $250.00 price objective on shares of Inspire Medical Systems in a research report on Wednesday. Jefferies Financial Group started coverage on shares of Inspire Medical Systems in a research note on Friday, January 19th. They set a “buy” rating and a $245.00 target price on the stock. Truist Financial reiterated a “buy” rating and issued a $280.00 target price on shares of Inspire Medical Systems in a research report on Wednesday, March 20th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $210.00 target price on shares of Inspire Medical Systems in a research report on Tuesday, January 2nd. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $271.29.
Read Our Latest Stock Analysis on Inspire Medical Systems
About Inspire Medical Systems
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
See Also
- Five stocks we like better than Inspire Medical Systems
- Dividend Capture Strategy: What You Need to Know
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
- Investing in Construction Stocks
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- What Is Dividend Yield and How Do You Calculate It?
- 7 Stocks That Will Drive the Weight Loss Drugs Market
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.